Risk Stratification of Resistant Hypertension in Chronic Kidney Disease∗  by Weinrauch, Larry A. et al.
Journal of the American College of Cardiology Vol. 61, No. 24, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00




Larry A. Weinrauch, MD,yz
Akshay S. Desai, MD, MPH,z
Hicham Skali, MD, MSC,z
John A. D’Elia, MDy
Boston, Massachusetts
The contribution of resistant hypertension (RH) to
morbidity and cost in chronic kidney disease (CKD) pop-
ulations should not be understated. Failure to control blood
pressure (BP) inevitably heralds renal deterioration as well as
accompanying increases in cardiovascular morbidity and
mortality. Successful antihypertensive treatment to guideline-
recommended targets is challenging, due to intravascular
volume expansion (sodium/ﬂuid retention) and treatment-
related adverse effects limiting patient adherence. The
NHANES (National Health and Nutrition Examination
Survey) and ALLHAT (Antihypertensive and Lipid
Lowering Treatment to Prevent Heart Attack Trial) trials
both demonstrated that CKD itself is a predictor of cardiac
events as a result of failure to achieve adequate BP control
(1,2). But to date the management of RH remains empirical,
due to a paucity of scientiﬁc clinical outcomes data with
suboptimal results.
See page 2461
In this issue of the Journal, data are presented with regard
to prevalence and prognosis of RH in 436 patients with
CKD (3). Consecutive patients with treated hypertension
(HTN) and CKD Stage II to V prospectively recruited from
4 nephrology clinics in Italy underwent 48-h ambulatory
blood pressure monitoring (ABPM) as well as 6 standard BP
measurements during the same time period. Patients were
classiﬁed into 4 phenotypes on the basis of achievement of*Editorials published in the Journal of the American College of Cardiology reﬂect the
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this paper to disclose.guideline-directed targets (4,5) at the time of enrollment
(Table 1): true resistance (RH); pseudoresistance; sustained;
or treatment responsive HTN.
With this granular categorization of HTN control
applying standard ofﬁce BP measurements and a single
session of ABPM, the authors deﬁned a gradient of risk for
RH in CKD patients. As anticipated, the risk for cardiorenal
events was highest in patients with “true” RH (concordant
elevation in ABPM and ofﬁce measurements). Surprisingly,
those with “sustained” and “pseudoresistant” HTN were
not at increased cardiovascular risk compared with control
subjects. Those with “sustained” HTN were, however, at
relatively higher risk for renal events.
These data from a CKD population mirror experience in
unselected populations highlighting the unfavorable prog-
nosis of “masked” HTN in comparison with the favorable
prognosis of “white coat” HTN (6). All of these patients,
however, were hypertensive. These results underscore the
importance of ABPM for “reclassiﬁcation” of the adequacy
of BP control in CKD. Use of ABPM identiﬁed a large
proportion (43% in this study) of subjects for whom BP
control seemed adequate by ofﬁce measurement but was
actually suboptimal. Such patients, overlooked during
routine surveillance, are under-treated (only 30% on regimen
of 3 antihypertensive drugs). Phenotyping with ABPM
offers the opportunity to improve clinical cardiorenal
outcomes by targeted antihypertensive therapy in the sus-
tained HTN group. By contrast, ﬁnding patients with
pseudoresistant HTN (of whom 100% are on regimen of 3
medications) might identify a group exposed to adverse
effects of complex antihypertensive treatment without
cardiovascular or renal beneﬁt. Similar observations have
been previously made in a dialysis population (7).
Although discordance between cardiorenal endpoints in
the sustained HTN group is challenging to explain, these
patients were younger than those with “true” RH (62 vs.
68 years) and less likely to have diabetes mellitus (25% vs.
64%). The lower incidence of left ventricular hypertrophy
and diabetes in those without true RH raises questions with
regard to links between insulin resistance and (lack of)
efﬁcacy of antihypertensive drugs in CKD populations. The
absence of an observed relationship between body mass
index, RH, and pseudoresistance in this study (3) contrasts
with prior studies linking obesity with increased sympathetic
outﬂow (8) and should spur future investigations.
Factors responsible for inadequate HTN control in pop-
ulations with true resistant or sustained HTN are not
clearly illuminated. Relevant factors in broader populations
with RH include poor adherence to prescribed therapies, use
of substances interfering with therapy (nonsteroidal anti-
inﬂammatory drugs, licorice, ephedrine, thyroid hormone,
contraceptives, and licit or illicit sympathomimetic drugs),
lifestyle factors including obesity and dietary sodium
intake, inadequate treatment (particularly inadequate use of
diuretic agents), untreated secondary causes (including reno-
vascular disease, obesity/sleep apnea, hyperaldosteronism, and
Table 1
Relationship Between a 48-h Classiﬁcation System for
Treated HTN in a Population With Chronic Renal
Disease and Follow-Up
Standard BP >130/80 Standard BP <130/80
ABPM >125/75 True Resistant Sustained
n ¼ 100 (23%) n ¼ 187 (43%)
CV events: 36 (36%) CV events: 40 (21%)
Renal events: 57 (57%) Renal events: 78 (42%)
ABPM <125/75 Pseudoresistant Controlled
n ¼ 31 (7%) n ¼ 118 (27%)
CV events: 8 (26%) CV events: 25 (21%)
Renal events: 5 (16%) Renal events: 25 (21%)
Blood pressure (BP) values are mm Hg.
ABPM ¼ 48-h ambulatory blood pressure monitoring; CV ¼ cardiovascular; HTN ¼ hypertension;
Standard BP ¼ 6 readings over 48 h.
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2469Cushing’s syndrome), insulin resistance/diabetes, and genetic
factors. Optimal management of patients with inadequate
ambulatory BP control in CKD requires additional investi-
gation. Many treatments effective in non-CKD populations
(e.g., sodium restriction, combination renin-angiotensin-
aldosterone system blockade, aldosterone antagonists) are
ineffective or associated with higher risk in populations with
CKD (9,10).
Nonpharmacologic therapies such as renal sympathetic
denervation are particularly promising in this regard (11,12).
Ongoing trials of this therapy in populations with RH
deﬁned by ofﬁce BP data should take account of these
outcome data, which highlight the potential for inadvertent
inclusion of lower-risk patients with “pseudoresistance” who
would not be expected to beneﬁt and exclusion of those
with “sustained” HTN and CKD who might be better
candidates. We must not repeat (uncontrolled, underpow-
ered) trial errors of unsuccessful renovascular manipulations
of past decades, chasing surrogate successes (13,14), and
avoidance of “falling behind,” while opening a deluge of
expensive procedures that expose patients to thus far unre-
ported adverse outcomes. We hope that the 48 open trials
currently listed at ClinicalTrials.gov (15) will modify ﬂawed
designs to answer appropriate safety and outcome questions.
These same reservations apply to pharmacologic agents
under investigation (aldosterone synthase inhibitor, nitric
oxide donor, and the like) (16) with none demonstrated to
be safe or useful in CKD populations.
There are study limitations, many acknowledged by the
authors. This study is observational, and important differ-
ences between groups and subsequent therapies might
account for variations in long-term outcomes. A largely
European population, from a single region, cannot be
generalized to other cohorts with HTN and CKD, and
cross-validation is needed. Nonetheless, this work highlights
a linkage between readily available technology and important
clinical endpoints (not surrogates). This report (3) adds to
the growing published data highlighting limitations of ofﬁce
BP measurements for management of HTN, exposes addi-
tional gaps in application of evidence-based antihypertensive
treatment, and provides a basis for future research.In clinical practice, there is increasing reliance on auto-
mated BP measurement taken in substandard conditions by
auxiliary personnel with limited clinical experience. Even
when properly done, random ofﬁce measurement of BP
might be an inadequate surrogate for the risk for long-term
outcomes. A single session of ABPM might provide a reli-
able estimate of the efﬁcacy of antihypertensive treatment
and more efﬁciently direct selection of appropriate therapy in
patients with CKD while costing less than a single session of
dialysis. Home BP self-monitoring has not been demon-
strated to mirror these clinical outcome results (17–19).
These ABPM-driven results suggest a need to re-evaluate
our appropriate device usage criteria to improve long-term
clinical outcomes and ﬁnancial impact among hypertensive
CKD populations. We should not accept false positive and
negative rates of this magnitude in deﬁning adequate BP
control in populations on the precipice of heart failure and
end-stage renal disease or the actual prevalence of RH that
represents 25% of the population identiﬁed as such.
An important observation worth emphasizing is that
a marker is used (APBM result) to reclassify patients and to
determine whether reclassiﬁcation has a measurable impact
on healthcare outcome in the population. Future studies will
determine whether treatment decisions on the basis of
knowledge of this marker improved outcomes among those
at high risk. It is time to determine whether measurement of
ABPM improves healthcare outcome and to determine the
impact of ABPM management reclassiﬁcations among
heart failure populations. Absent such studies, a potentially
useful, noninvasive technology will remain underused, and
the ﬁnancial impact of poorly controlled HTN on prevalence
of end-stage renal disease and heart failure will continue
to increase.
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